Physician profile
Paula Lee
NPI 1972985596
$1,296.48
in general payments reported to CMS, 2019-2025
23 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.59 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.89 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $187.36 | 2025 | |
| Ucb, INC. | $156.49 | 2025 | Zilbrysq, Nayzilam, Rystiggo |
| Abbvie INC. | $144.21 | 2025 | |
| Inspire Medical Systems, INC. | $121.07 | 2025 | Inspire |
| Neurocrine Biosciences, INC. | $67.34 | 2025 | |
| Genentech USA, INC. | $61.90 | 2025 | Ocrevus Zunovo, Evrysdi |
| Axsome Therapeutics, INC. | $59.79 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $58.21 | 2025 | Nuplazid |
| Pfizer INC. | $54.50 | 2025 | |
| Merz Pharmaceuticals, LLC | $45.08 | 2025 | Xeomin, Inbrija |
| Alexion Pharmaceuticals, INC. | $42.25 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $39.10 | 2025 | |
| Ge Healthcare | $38.13 | 2025 | |
| Tg Therapeutics, INC. | $34.14 | 2025 | |
| Lilly USA, LLC | $30.74 | 2025 | Kisunla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.34 | 2025 | |
| Novocure INC. | $23.86 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $20.58 | 2025 | |
| C2n Diagnostics, LLC | $19.01 | 2025 | Precivityad2 |
| Argenx US, INC. | $17.93 | 2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $16.46 | 2025 | Austedo Xr |
| Neurelis, INC. | $16.02 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $14.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.